JP2019088334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019088334A5 JP2019088334A5 JP2019052699A JP2019052699A JP2019088334A5 JP 2019088334 A5 JP2019088334 A5 JP 2019088334A5 JP 2019052699 A JP2019052699 A JP 2019052699A JP 2019052699 A JP2019052699 A JP 2019052699A JP 2019088334 A5 JP2019088334 A5 JP 2019088334A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hla
- genetically modified
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004962 mammalian cell Anatomy 0.000 claims description 73
- 150000007523 nucleic acids Chemical group 0.000 claims description 65
- 210000004027 cell Anatomy 0.000 claims description 60
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 31
- 238000012239 gene modification Methods 0.000 claims description 29
- 230000005017 genetic modification Effects 0.000 claims description 29
- 235000013617 genetically modified food Nutrition 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 210000000130 stem cell Anatomy 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 239000013604 expression vector Substances 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims description 16
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 206010062016 Immunosuppression Diseases 0.000 claims description 10
- 230000005847 immunogenicity Effects 0.000 claims description 10
- 230000001506 immunosuppresive effect Effects 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 8
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 5
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 241000699802 Cricetulus griseus Species 0.000 claims description 4
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 4
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 4
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 4
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 4
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 4
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 4
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 4
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 3
- 210000001130 astrocyte Anatomy 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 210000002510 keratinocyte Anatomy 0.000 claims description 3
- 210000001178 neural stem cell Anatomy 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 230000005740 tumor formation Effects 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 238000001516 cell proliferation assay Methods 0.000 claims description 2
- 238000002784 cytotoxicity assay Methods 0.000 claims description 2
- 231100000263 cytotoxicity test Toxicity 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 210000001626 skin fibroblast Anatomy 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims 25
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 8
- 235000004279 alanine Nutrition 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 8
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 230000036560 skin regeneration Effects 0.000 claims 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 15
- 108010024164 HLA-G Antigens Proteins 0.000 description 15
- 230000035772 mutation Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 101150024418 HLA-G gene Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 102000047279 human B2M Human genes 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068195A JP7379410B2 (ja) | 2012-07-31 | 2021-04-14 | Ｈｌａ ｇ改変された細胞および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261677739P | 2012-07-31 | 2012-07-31 | |
| US61/677,739 | 2012-07-31 | ||
| JP2018028816A JP6502544B2 (ja) | 2012-07-31 | 2018-02-21 | Ｈｌａ ｇ改変された細胞および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018028816A Division JP6502544B2 (ja) | 2012-07-31 | 2018-02-21 | Ｈｌａ ｇ改変された細胞および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068195A Division JP7379410B2 (ja) | 2012-07-31 | 2021-04-14 | Ｈｌａ ｇ改変された細胞および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019088334A JP2019088334A (ja) | 2019-06-13 |
| JP2019088334A5 true JP2019088334A5 (enExample) | 2019-09-26 |
| JP7294838B2 JP7294838B2 (ja) | 2023-06-20 |
Family
ID=50028654
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525519A Active JP6297559B2 (ja) | 2012-07-31 | 2013-07-30 | Ｈｌａｇ改変された細胞および方法 |
| JP2018028816A Active JP6502544B2 (ja) | 2012-07-31 | 2018-02-21 | Ｈｌａ ｇ改変された細胞および方法 |
| JP2019052699A Active JP7294838B2 (ja) | 2012-07-31 | 2019-03-20 | Ｈｌａ ｇ改変された細胞および方法 |
| JP2021068195A Active JP7379410B2 (ja) | 2012-07-31 | 2021-04-14 | Ｈｌａ ｇ改変された細胞および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525519A Active JP6297559B2 (ja) | 2012-07-31 | 2013-07-30 | Ｈｌａｇ改変された細胞および方法 |
| JP2018028816A Active JP6502544B2 (ja) | 2012-07-31 | 2018-02-21 | Ｈｌａ ｇ改変された細胞および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068195A Active JP7379410B2 (ja) | 2012-07-31 | 2021-04-14 | Ｈｌａ ｇ改変された細胞および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9714280B2 (enExample) |
| EP (4) | EP4015530A1 (enExample) |
| JP (4) | JP6297559B2 (enExample) |
| KR (4) | KR102366081B1 (enExample) |
| CN (2) | CN113151179A (enExample) |
| AU (2) | AU2013296564C1 (enExample) |
| CA (1) | CA2882028C (enExample) |
| ES (2) | ES2837487T3 (enExample) |
| SG (1) | SG11201500799YA (enExample) |
| WO (1) | WO2014022423A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014513948A (ja) | 2011-04-20 | 2014-06-19 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | β２ミクログロブリン欠損細胞 |
| ES2837487T3 (es) | 2012-07-31 | 2021-06-30 | Agex Therapeutics Inc | Métodos para producir células HLA-G modificadas |
| US10041077B2 (en) | 2014-04-09 | 2018-08-07 | Dna2.0, Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
| WO2015157579A2 (en) | 2014-04-09 | 2015-10-15 | Dna2.0, Inc. | Enhanced nucleic acid constructs for eukaryotic gene expression |
| SG11201704291QA (en) * | 2014-11-26 | 2017-06-29 | Accelerated Biosciences Corp | Induced hepatocytes and uses thereof |
| US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US20220241345A1 (en) * | 2015-10-02 | 2022-08-04 | The Regents Of The University Of California | Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke |
| LT3359671T (lt) | 2015-10-08 | 2021-12-10 | Dna Twopointo Inc. | Dnr vektoriai, transpozonai ir transpozazės, skirti eukariotinio genomo modifikacijai |
| JP7519660B2 (ja) * | 2016-06-14 | 2024-07-22 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| EP3491015A4 (en) | 2016-07-26 | 2020-02-26 | The University of North Carolina at Chapel Hill | VECTOR-MEDIATED IMMUNOLOLERANCE IN THE EYE |
| AU2018208614A1 (en) | 2017-01-10 | 2019-07-11 | The General Hospital Corporation | Modified T cells and methods of their use |
| GB2588249B (en) * | 2017-06-12 | 2023-01-04 | Sinai Health Sys | Allograft tolerance without the need for systemic immune suppression |
| WO2019133853A1 (en) * | 2017-12-28 | 2019-07-04 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared antigens |
| CN119752801A (zh) * | 2018-08-01 | 2025-04-04 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| BR112021011273A2 (pt) * | 2018-12-14 | 2021-09-28 | Promethera Therapeutics Sa | Composição celular que compreende células progenitoras do fígado que expressam hla-e |
| WO2020120666A1 (en) | 2018-12-14 | 2020-06-18 | Promethera Biosciences S.A./N.V. | Liver progenitor cells expressing hla-g, and method for obtaining these cells compositions comprising said cells and their use |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| CN115151636A (zh) * | 2020-02-10 | 2022-10-04 | 鲁比厄斯治疗法股份有限公司 | 包含hla-g多肽的经工程改造的红系细胞及其使用方法 |
| US20230203445A1 (en) * | 2020-05-26 | 2023-06-29 | Healios K.K. | Hypoimmunogenic cells |
| CN114746152A (zh) * | 2020-08-23 | 2022-07-12 | 应用干细胞有限公司 | Hla-f修饰的细胞和方法 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| CN113234664B (zh) * | 2021-05-11 | 2024-05-10 | 澳门大学 | 一种胰腺祖细胞的制备方法及其应用 |
| JP2024540987A (ja) * | 2021-10-21 | 2024-11-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | 低免疫細胞 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5534423A (en) | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
| US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| US6013517A (en) | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
| US5650135A (en) | 1994-07-01 | 1997-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5741657A (en) | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
| US5744320A (en) | 1995-06-07 | 1998-04-28 | Promega Corporation | Quenching reagents and assays for enzyme-mediated luminescence |
| US6982431B2 (en) | 1998-08-31 | 2006-01-03 | Molecular Devices Corporation | Sample analysis systems |
| US6031094A (en) | 1998-07-23 | 2000-02-29 | The Regents Of The University Of California | Beta-lactam substrates and uses thereof |
| US7005252B1 (en) | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
| CA2445260C (en) | 2001-04-23 | 2011-02-01 | Amaxa Gmbh | Buffer solution for electroporation and a method comprising the use of the same |
| EP1543110A4 (en) | 2002-05-17 | 2006-09-06 | Sinai School Medicine | POPULATION OF DEFINITIVE ENDODERMIC CELLS AND MESODERMAL |
| CA2514564A1 (en) | 2003-01-31 | 2005-07-26 | Promega Corporation | Covalent tethering of functional groups to proteins |
| US7960166B2 (en) | 2003-05-21 | 2011-06-14 | The General Hospital Corporation | Microfabricated compositions and processes for engineering tissues containing multiple cell types |
| ES2354160T3 (es) * | 2003-10-21 | 2011-03-10 | Merck Serono Sa | Secuencia de adn mínima que actúa como un aislante de cromatina, y su uso en la expresión de proteínas. |
| US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
| JP5291341B2 (ja) * | 2004-11-08 | 2013-09-18 | クロマジェニックス ベー ヴェー | タンパク質を高レベルで発現する宿主細胞の選定 |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| EP1937326B1 (en) * | 2005-10-21 | 2018-09-12 | CellResearch Corporation Pte Ltd | Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom |
| US8048999B2 (en) | 2005-12-13 | 2011-11-01 | Kyoto University | Nuclear reprogramming factor |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US20090156532A1 (en) * | 2006-01-24 | 2009-06-18 | The University Of Chicago | SNP BINDING SITE FOR microRNAs IN HLA-G |
| WO2007091078A2 (en) * | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| US8420367B2 (en) | 2006-10-30 | 2013-04-16 | Promega Corporation | Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression |
| US8647871B2 (en) * | 2007-03-30 | 2014-02-11 | Escape Therapeutics, Inc. | Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells |
| WO2011071476A2 (en) * | 2008-11-14 | 2011-06-16 | Life Technologies Corporation | Compositions and methods for engineering cells |
| US8592211B2 (en) | 2009-03-20 | 2013-11-26 | The Rockefeller University | Enhanced PiggyBac transposon and methods for transposon mutagenesis |
| US8048675B1 (en) | 2010-05-12 | 2011-11-01 | Ipierian, Inc. | Integration-free human induced pluripotent stem cells from blood |
| ES2837487T3 (es) | 2012-07-31 | 2021-06-30 | Agex Therapeutics Inc | Métodos para producir células HLA-G modificadas |
| CN103333861A (zh) * | 2013-06-03 | 2013-10-02 | 浙江省台州医院 | 特异性表达hla-g1抗原的细胞株k562 |
| CN111808819A (zh) * | 2020-05-26 | 2020-10-23 | 台州恩泽医疗中心(集团) | 表达hla-g3异构体标准蛋白的细胞株及其应用 |
-
2013
- 2013-07-30 ES ES18211100T patent/ES2837487T3/es active Active
- 2013-07-30 SG SG11201500799YA patent/SG11201500799YA/en unknown
- 2013-07-30 KR KR1020207033804A patent/KR102366081B1/ko active Active
- 2013-07-30 WO PCT/US2013/052767 patent/WO2014022423A2/en not_active Ceased
- 2013-07-30 KR KR1020197036122A patent/KR102184947B1/ko active Active
- 2013-07-30 CA CA2882028A patent/CA2882028C/en active Active
- 2013-07-30 CN CN202110063720.2A patent/CN113151179A/zh active Pending
- 2013-07-30 EP EP21209423.9A patent/EP4015530A1/en active Pending
- 2013-07-30 AU AU2013296564A patent/AU2013296564C1/en active Active
- 2013-07-30 JP JP2015525519A patent/JP6297559B2/ja active Active
- 2013-07-30 ES ES13825511T patent/ES2716577T3/es active Active
- 2013-07-30 CN CN201380051169.3A patent/CN105612176B/zh active Active
- 2013-07-30 KR KR1020157005165A patent/KR101923632B1/ko active Active
- 2013-07-30 EP EP18211100.5A patent/EP3483178B1/en active Active
- 2013-07-30 EP EP20196775.9A patent/EP3805261A1/en not_active Withdrawn
- 2013-07-30 KR KR1020187034048A patent/KR102055438B1/ko active Active
- 2013-07-30 EP EP13825511.2A patent/EP2880054B1/en active Active
-
2015
- 2015-01-28 US US14/608,004 patent/US9714280B2/en active Active
-
2017
- 2017-06-16 US US15/625,964 patent/US10502738B2/en active Active
-
2018
- 2018-02-21 JP JP2018028816A patent/JP6502544B2/ja active Active
- 2018-08-23 AU AU2018220087A patent/AU2018220087B2/en active Active
-
2019
- 2019-03-20 JP JP2019052699A patent/JP7294838B2/ja active Active
- 2019-10-22 US US16/659,918 patent/US11977073B2/en active Active
-
2020
- 2020-03-27 US US16/832,321 patent/US20200309776A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068195A patent/JP7379410B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019088334A5 (enExample) | ||
| JP2015529457A5 (enExample) | ||
| JP6502544B2 (ja) | Ｈｌａ ｇ改変された細胞および方法 | |
| JP6970106B2 (ja) | Ｖｃｎエンハンサー組成物およびその使用方法 | |
| ES2601845T3 (es) | Aislamiento y purificación de células madre hematopoyéticas a partir de lipoaspirados post-liposucción | |
| JP2021534806A (ja) | ユニバーサルドナー細胞 | |
| JPWO2021041316A5 (enExample) | ||
| CN114026225A (zh) | 安全的免疫隐形细胞 | |
| IL293552A (en) | Modulators of the immune escape mechanism for universal cell therapy | |
| EP3831945A1 (en) | Protein heterodimer and use thereof | |
| CN115135330A (zh) | 修饰的干细胞及其使用方法 | |
| JP2022551478A (ja) | 持続的トランスジーン発現を伴う細胞 | |
| CA3100262A1 (en) | Compositions and methods for haematopoietic stem cell transplantation | |
| Lim et al. | Microporation is a valuable transfection method for efficient gene delivery into human umbilical cord blood-derived mesenchymal stem cells | |
| JP7016556B2 (ja) | 脳由来神経栄養因子を発現する間葉系幹細胞およびその用途 | |
| CN117716026A (zh) | 具有氧化应激抗性的间充质干细胞、其制备方法及用途 | |
| WO2016112779A1 (en) | Modified cells evoking reduced immunogenic responses | |
| JP5745419B2 (ja) | 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法 | |
| JP2021503008A (ja) | 造血幹細胞および前駆細胞移植療法のための組成物および方法 | |
| CN120615119A (zh) | 用于同种异体细胞疗法以覆盖全球、种族或特定疾病群体的免疫相容细胞 | |
| JP6691756B2 (ja) | 合成ペプチドを用いた神経幹細胞の生産方法 | |
| CN116396940A (zh) | 造血干祖细胞及其制备方法和用途 | |
| JP7144829B2 (ja) | 安全性と抗炎症作用を高めた間葉系幹細胞 | |
| Carretero et al. | Applicability of bioengineered human skin: from preclinical skin humanized mouse models to clinical regenerative therapies | |
| CN100408677C (zh) | 一种bdnf基因修饰的间充质干细胞的构建方法 |